Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Plasma suPAR is lowered by smoking cessation - a randomised controlled study

Research output: Contribution to journalJournal articleResearchpeer-review

DOI

  1. A totally new system is needed for drug research and development

    Research output: Contribution to journalLetterResearchpeer-review

  2. Patients not patents: Drug research and development as a public enterprise

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Prediction of coronary heart disease or heart failure using high-sensitivity cardiac troponin T: a pilot study

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Anti-inflammatory effects of exercise: role in diabetes and cardiovascular disease

    Research output: Contribution to journalReviewResearchpeer-review

  5. Familial hypercholesterolaemia: cholesterol efflux and coronary disease

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Soluble Urokinase Receptor (SuPAR) in COVID-19-Related AKI

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Association Between Elevated suPAR, a New Biomarker of Inflammation, and Accelerated Aging

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Validation of suPAR turbidimetric assay on Cobas® (c502 and c702) and comparison to suPAR ELISA

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Elevated suPAR Is an Independent Risk Marker for Incident Kidney Disease in Acute Medical Patients

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

BACKGROUND: Soluble urokinase plasminogen activator receptor (suPAR) is a stable inflammatory biomarker. In patients, suPAR is a marker of disease presence, severity and prognosis. In the general population, suPAR is predictive of disease development, such as diabetes and cardiovascular disease and, in smokers, predictive of long-term lung cancer development. Whether smoking cessation impacts the suPAR level is unknown.

MATERIALS AND METHODS: Forty-eight smokers were randomized into three groups of 16: 1) continued to smoke 20 cigarettes per day, 2) refrained from smoking and used transdermal nicotine patches and 3) refrained from smoking and used placebo patches. Non-smokers were included for comparison. suPAR and C-reactive protein (CRP) levels were measured by ELISA.

RESULTS: At baseline, the suPAR level was significantly higher in the 48 smokers (median 3.2 ng/ml, IQR (2.5-3.9)) than in 46 never smokers (1.9 ng/ml (1.7-2.2)). In smokers randomised to smoking cessation, suPAR levels after four weeks of stopping were decreased and no longer significantly different from the never smokers values. SuPAR decreased in both those who received a placebo as well as nicotine patch. Interestingly, those with the highest suPAR level at time of smoking were also those with the highest level of suPAR after smoking cessation. In contrast, smoking or smoking cessation had no influence on CRP levels.

CONCLUSION: Our study suggest that the suPAR level may aid to personalize the risk of smoking by identifying those smokers with the highest risk of developing disease and who may have the most benefit of smoking cessation. This article is protected by copyright. All rights reserved.

Original languageEnglish
JournalEuropean Journal of Clinical Investigation
Volume46
Issue number4
Pages (from-to)305-311
ISSN0014-2972
DOIs
Publication statusPublished - Apr 2016

ID: 46031025